Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease
Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease
复制标题
DOI：
10.1194/jlr.ra120000746
复制
发表时间：
2020-09-01
影响因子：
6.5
通讯作者：
Li, Jian-Jun
中科院分区：
文献类型：
--
作者：
Cao, Ye-Xuan;Zhang, Hui-Wen;Li, Jian-Jun
富含TG的脂蛋白（TRL）相关生物标志物，包括TRL-胆固醇（TRL-C）、残留样脂蛋白颗粒胆固醇（RLP-C）和apoC-III与动脉粥样硬化有关。然而，它们的预后价值尚未完全确定，特别是对于既往患有 CAD 的患者。本研究旨在探讨 CAD 二级预防中 TRL-C、RLP-C 和 apoC-III 与心血管事件 (CVE) 的关联。直接测量血浆TRL-C、RLP-C和总apoC-III。对总共 4,355 名经血管造影确诊患有 CAD 的参与者进行了随访，了解 CVE 的发生情况。在中位随访期 5.1 年（四分位间距：3.9-6.4 年）内，发生了 543 起事件（12.5%）。发生 CVE 的患者的 TRL-C、RLP-C 和 apoC-III 水平显着高于未发生 CVE 的患者。多变量 Cox 分析表明，TRL-C、RLP-C 和 apoC-III 的对数单位增加会使 CVE 风险分别增加 49% (95% CI: 1.16-1.93)、21% (95% CI: 1.09-1.35) 和 40% (95% CI: 1.11-1.77)。高 TRL-C、RLP-C 和 apoC-III 也是 LDL-C 水平个体 CVE 的独立预测因素
TG-rich lipoprotein (TRL)-related biomarkers, including TRL-cholesterol (TRL-C), remnant-like lipoprotein particle-cholesterol (RLP-C), and apoC-III have been associated with atherosclerosis. However, their prognostic values have not been fully determined, especially in patients with previous CAD. This study aimed to examine the associations of TRL-C, RLP-C, and apoC-III with incident cardiovascular events (CVEs) in the setting of secondary prevention of CAD. Plasma TRL-C, RLP-C, and total apoC-III were directly measured. A total of 4,355 participants with angiographically confirmed CAD were followed up for the occurrence of CVEs. During a median follow-up period of 5.1 years (interquartile range: 3.9-6.4 years), 543 (12.5%) events occurred. Patients with incident CVEs had significantly higher levels of TRL-C, RLP-C, and apoC-III than those without events. Multivariable Cox analysis indicated that a log unit increase in TRL-C, RLP-C, and apoC-III increased the risk of CVEs by 49% (95% CI: 1.16-1.93), 21% (95% CI: 1.09-1.35), and 40% (95% CI: 1.11-1.77), respectively. High TRL-C, RLP-C, and apoC-III were also independent predictors of CVEs in individuals with LDL-C levels